This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Oct 2021

Nobel Prize in Medicine for the discovery of TRPV1

“The discovery of the TRPV1 receptor has laid the foundation for the development of innovative non-opioid pain therapies.” Jan Adams, MD, Chief Scientific Officer, Grünenthal

The 2021 Nobel Prize in Physiology or Medicine has been awarded to Professor David Julius and Professor Ardem Patapoutian for their research into temperature and pressure-sensitive receptors, including the discovery of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, which plays a critical role in pain signalling

Leveraging Nobel Prize-Winning Science to Deliver Pain Relief for Patients Today

What the scientists did

The researchers set out to better understand how we perceive our environment and the mechanisms behind how we sense different stimuli, including heat and pressure.

Professor David Julius of the University of California, San Francisco, USA, first investigated how the chemical compound capsaicin causes a burning sensation when we eat chillies. He and his team were able to identify the single gene responsible for the capsaicin receptor and, therefore, capsaicin and temperature sensitivity. This receptor was later named TRPV1.

Professor Ardem Patapoutian and his team looked into how humans sense touch and subsequently identified two genes responsible for two new ion channels sensitive to pressure; PIEZO1 and PIEZO2.

What this means for patients

These discoveries have significantly contributed to understanding the mechanics behind pain and have allowed Grünenthal scientists to investigate new non-opioid treatment options.

The discovery of the TRPV1 receptor specifically has been integral to the development of a non-opioid, non-systemic cutaneous patch based on capsaicin which is already available to patients for the treatment of peripheral neuropathic pain (PNP) in adults either alone or in combination with other medicinal products*. This localised procedure can provide sustained pain relief that lasts for up to three months without any known drug-drug interactions and without the same harmful central nervous system side effects common with currently available systemic (or oral) treatments for PNP. Grünenthal continues to investigate this non-opioid pain medicine in additional patient groups such as those with post-surgical neuropathic pain.

In addition, Resiniferatoxin[JC1] , a highly potent TRPV1 agonist, is currently being investigated for its efficacy, safety and tolerability in pain related to osteoarthritis of the knee. This progressive condition currently cannot be cured. Targeting TRPV1 through this investigational medicine has the potential to achieve long-lasting pain relief and functional improvement for patients.

Mentioned Companies
Grunenthal GmbH
View company profile